About Alejandro
Alejandro Luna joined OLIVARES in 1996 and being made partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices. He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.Alejandro Luna has been alternately dubbed “an extraordinary litigator, active at every level,” “responsive and insightful,” and “a knowledgeable IP practitioner offering creative and cost-effective advice” by his peers, according to IAM Patent 1000, while World Trademark Review’s WTR 1000 called him “a reliable ally for any party in a dispute”.Since joining OLIVARES in 1996 and becoming partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices.He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.As one of the few patent and regulatory litigation experts in the country, Mr. Luna has played a crucial role in updating Mexico’s intellectual property (IP) system. He participated in questioning the constitutionality of certain provisions of Mexico’s Industrial Property Law and the Health Law and its regulation. He sponsored an important proposal to modify the litigation and enforcement systems that made it easier to obtain monetary compensation for violations of IP rights.Mr. Luna spearheaded a more than a ten-year litigation strategy that incorporated regulation changes and lobbying, resulting in an important precedent for the patent linkage regulation and life terms of pipeline pharmaceutical patents in Mexico.As a result of his involvement, Mr. Luna was selected as the delegate to represent the Asociación Mexicana de Industrias de Investigación Farmacéutica, AC (AMIIF), the industry association for R&D pharmaceutical companies that do business in Mexico, in negotiations concerning the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) agreement, the free trade agreement between Mexico and the European Union, and the United States-Mexico-Canada Agreement (USMCA/ T-MEC), which replaced NAFTA.Mr. Luna’s practice is not devoted exclusively to life sciences; he represents clients across a myriad of industries. He has successfully litigated pharmaceutical patents and pioneered administrative court actions to seek recognition of DPE rights (regulatory data protection submitted to the regulatory agency), which are not specifically recognized under Mexican law.His commitment to just and fair law extends to his overall promise of client satisfaction; he acts on behalf of his clients as an attorney and a lobbyist, pushing for changes to the law as necessary to best serve his clients.Mr. Luna is also the author of several articles on patents, litigation, and regulatory issues in the pharmaceutical industries. He is part time professor at the Universidad Nacional Autónoma de México (UNAM), in the IP Master of Law and the Health Law program and recently obtained a Doctorate in Law (summa cum laude) with his doctoral thesis, titled “The Impact of International Treaties in the Mexican Patent Law, Pharmaceutical Patents and the Corresponding Enforcement”.Representative CasesLuna appealed several refusals of authorizations for medicines containing “cannabis,” prior to the Constitutional amendments to legalize the medical use of cannabis and other narcotics.Luna has been deeply involved in building strategies to maximize IP rights for key clients in the pharmaceutical industry. He is a pioneer in the litigation of pharmaceuticals and biologics and has successfully defended the exclusive rights of innovators by obliging regulators to suspend the approval of “biosimilars” when regulatory requirements have not been met.After 8 years of litigation, Mr. Luna rescued one of Mexico’s leading fashion trademarks, which had been “kidnapped” by loopholes in the Mexican trademark law.Luna participated as an expert on the interpretation of the Mexican patent law and patent utility requirements in a NAFTA arbitration examining the Canadian utility standard and doctrine of sound prediction. There are few opportunities for IP attorneys to participate in a Free Trade Agreement arbitration.He has been considered the first patent linkage litigator in the countryLuna advocate to have a direct and independent civil venue to claim damages derived from the violation of patent and trademark rights.AwardsChambers Global – Mexico, Band 1Chambers Latin America – IP, Band 1Chambers Latin America – Life Sciences, Band 1IAM Patent 1000 – Litigation, GoldLatin Lawyer 250, Tier 1Legal 500, Tier 1MIP – IP StarWho’s Who Legal, Tier 1World’s Guide to the Leading Patent Law Practitioners, Tier 1WTR 1000 – Silver – Enforcement & LitigationEducationFranklin Pierce Law CenterLLM, Intellectual Property Law, 2002Universidad PanamericanaDiploma on Amparo Law, 2000Universidad LatinoamericanaJuris Doctor, 1996Universidad Nacional Autónma de MéxicoDoctorate in Law, 2020
Alejandro Luna joined OLIVARES in 1996 and being made partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices. He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.Alejandro Luna has been alternately dubbed “an extraordinary litigator, active at every level,” “responsive and insightful,” and “a knowledgeable IP practitioner offering creative and cost-effective advice” by his peers, according to IAM Patent 1000, while World Trademark Review’s WTR 1000 called him “a reliable ally for any party in a dispute”.Since joining OLIVARES in 1996 and becoming partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices.He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.As one of the few patent and regulatory litigation experts in the country, Mr. Luna has played a crucial role in updating Mexico’s intellectual property (IP) system. He participated in questioning the constitutionality of certain provisions of Mexico’s Industrial Property Law and the Health Law and its regulation. He sponsored an important proposal to modify the litigation and enforcement systems that made it easier to obtain monetary compensation for violations of IP rights.Mr. Luna spearheaded a more than a ten-year litigation strategy that incorporated regulation changes and lobbying, resulting in an important precedent for the patent linkage regulation and life terms of pipeline pharmaceutical patents in Mexico.As a result of his involvement, Mr. Luna was selected as the delegate to represent the Asociación Mexicana de Industrias de Investigación Farmacéutica, AC (AMIIF), the industry association for R&D pharmaceutical companies that do business in Mexico, in negotiations concerning the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) agreement, the free trade agreement between Mexico and the European Union, and the United States-Mexico-Canada Agreement (USMCA/ T-MEC), which replaced NAFTA.Mr. Luna’s practice is not devoted exclusively to life sciences; he represents clients across a myriad of industries. He has successfully litigated pharmaceutical patents and pioneered administrative court actions to seek recognition of DPE rights (regulatory data protection submitted to the regulatory agency), which are not specifically recognized under Mexican law.His commitment to just and fair law extends to his overall promise of client satisfaction; he acts on behalf of his clients as an attorney and a lobbyist, pushing for changes to the law as necessary to best serve his clients.Mr. Luna is also the author of several articles on patents, litigation, and regulatory issues in the pharmaceutical industries. He is part time professor at the Universidad Nacional Autónoma de México (UNAM), in the IP Master of Law and the Health Law program and recently obtained a Doctorate in Law (summa cum laude) with his doctoral thesis, titled “The Impact of International Treaties in the Mexican Patent Law, Pharmaceutical Patents and the Corresponding Enforcement”.Representative CasesLuna appealed several refusals of authorizations for medicines containing “cannabis,” prior to the Constitutional amendments to legalize the medical use of cannabis and other narcotics.Luna has been deeply involved in building strategies to maximize IP rights for key clients in the pharmaceutical industry. He is a pioneer in the litigation of pharmaceuticals and biologics and has successfully defended the exclusive rights of innovators by obliging regulators to suspend the approval of “biosimilars” when regulatory requirements have not been met.After 8 years of litigation, Mr. Luna rescued one of Mexico’s leading fashion trademarks, which had been “kidnapped” by loopholes in the Mexican trademark law.Luna participated as an expert on the interpretation of the Mexican patent law and patent utility requirements in a NAFTA arbitration examining the Canadian utility standard and doctrine of sound prediction. There are few opportunities for IP attorneys to participate in a Free Trade Agreement arbitration.He has been considered the first patent linkage litigator in the countryLuna advocate to have a direct and independent civil venue to claim damages derived from the violation of patent and trademark rights.AwardsChambers Global – Mexico, Band 1Chambers Latin America – IP, Band 1Chambers Latin America – Life Sciences, Band 1IAM Patent 1000 – Litigation, GoldLatin Lawyer 250, Tier 1Legal 500, Tier 1MIP – IP StarWho’s Who Legal, Tier 1World’s Guide to the Leading Patent Law Practitioners, Tier 1WTR 1000 – Silver – Enforcement & LitigationEducationFranklin Pierce Law CenterLLM, Intellectual Property Law, 2002Universidad PanamericanaDiploma on Amparo Law, 2000Universidad LatinoamericanaJuris Doctor, 1996Universidad Nacional Autónma de MéxicoDoctorate in Law, 2020
Alejandro Luna joined OLIVARES in 1996 and being made partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices. He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.
Alejandro Luna has been alternately dubbed “an extraordinary litigator, active at every level,” “responsive and insightful,” and “a knowledgeable IP practitioner offering creative and cost-effective advice” by his peers, according to IAM Patent 1000, while World Trademark Review’s WTR 1000 called him “a reliable ally for any party in a dispute”.
Since joining OLIVARES in 1996 and becoming partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices.
He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.
As one of the few patent and regulatory litigation experts in the country, Mr. Luna has played a crucial role in updating Mexico’s intellectual property (IP) system. He participated in questioning the constitutionality of certain provisions of Mexico’s Industrial Property Law and the Health Law and its regulation. He sponsored an important proposal to modify the litigation and enforcement systems that made it easier to obtain monetary compensation for violations of IP rights.
Mr. Luna spearheaded a more than a ten-year litigation strategy that incorporated regulation changes and lobbying, resulting in an important precedent for the patent linkage regulation and life terms of pipeline pharmaceutical patents in Mexico.
As a result of his involvement, Mr. Luna was selected as the delegate to represent the Asociación Mexicana de Industrias de Investigación Farmacéutica, AC (AMIIF), the industry association for R&D pharmaceutical companies that do business in Mexico, in negotiations concerning the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) agreement, the free trade agreement between Mexico and the European Union, and the United States-Mexico-Canada Agreement (USMCA/ T-MEC), which replaced NAFTA.
Mr. Luna’s practice is not devoted exclusively to life sciences; he represents clients across a myriad of industries. He has successfully litigated pharmaceutical patents and pioneered administrative court actions to seek recognition of DPE rights (regulatory data protection submitted to the regulatory agency), which are not specifically recognized under Mexican law.
His commitment to just and fair law extends to his overall promise of client satisfaction; he acts on behalf of his clients as an attorney and a lobbyist, pushing for changes to the law as necessary to best serve his clients.
Mr. Luna is also the author of several articles on patents, litigation, and regulatory issues in the pharmaceutical industries. He is part time professor at the Universidad Nacional Autónoma de México (UNAM), in the IP Master of Law and the Health Law program and recently obtained a Doctorate in Law (summa cum laude) with his doctoral thesis, titled “The Impact of International Treaties in the Mexican Patent Law, Pharmaceutical Patents and the Corresponding Enforcement”.
Alejandro Luna joined OLIVARES in 1996 and being made partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices. He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.Alejandro Luna has been alternately dubbed “an extraordinary litigator, active at every level,” “responsive and insightful,” and “a knowledgeable IP practitioner offering creative and cost-effective advice” by his peers, according to IAM Patent 1000, while World Trademark Review’s WTR 1000 called him “a reliable ally for any party in a dispute”.Since joining OLIVARES in 1996 and becoming partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices.He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.As one of the few patent and regulatory litigation experts in the country, Mr. Luna has played a crucial role in updating Mexico’s intellectual property (IP) system. He participated in questioning the constitutionality of certain provisions of Mexico’s Industrial Property Law and the Health Law and its regulation. He sponsored an important proposal to modify the litigation and enforcement systems that made it easier to obtain monetary compensation for violations of IP rights.Mr. Luna spearheaded a more than a ten-year litigation strategy that incorporated regulation changes and lobbying, resulting in an important precedent for the patent linkage regulation and life terms of pipeline pharmaceutical patents in Mexico.As a result of his involvement, Mr. Luna was selected as the delegate to represent the Asociación Mexicana de Industrias de Investigación Farmacéutica, AC (AMIIF), the industry association for R&D pharmaceutical companies that do business in Mexico, in negotiations concerning the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) agreement, the free trade agreement between Mexico and the European Union, and the United States-Mexico-Canada Agreement (USMCA/ T-MEC), which replaced NAFTA.Mr. Luna’s practice is not devoted exclusively to life sciences; he represents clients across a myriad of industries. He has successfully litigated pharmaceutical patents and pioneered administrative court actions to seek recognition of DPE rights (regulatory data protection submitted to the regulatory agency), which are not specifically recognized under Mexican law.His commitment to just and fair law extends to his overall promise of client satisfaction; he acts on behalf of his clients as an attorney and a lobbyist, pushing for changes to the law as necessary to best serve his clients.Mr. Luna is also the author of several articles on patents, litigation, and regulatory issues in the pharmaceutical industries. He is part time professor at the Universidad Nacional Autónoma de México (UNAM), in the IP Master of Law and the Health Law program and recently obtained a Doctorate in Law (summa cum laude) with his doctoral thesis, titled “The Impact of International Treaties in the Mexican Patent Law, Pharmaceutical Patents and the Corresponding Enforcement”.Representative CasesLuna appealed several refusals of authorizations for medicines containing “cannabis,” prior to the Constitutional amendments to legalize the medical use of cannabis and other narcotics.Luna has been deeply involved in building strategies to maximize IP rights for key clients in the pharmaceutical industry. He is a pioneer in the litigation of pharmaceuticals and biologics and has successfully defended the exclusive rights of innovators by obliging regulators to suspend the approval of “biosimilars” when regulatory requirements have not been met.After 8 years of litigation, Mr. Luna rescued one of Mexico’s leading fashion trademarks, which had been “kidnapped” by loopholes in the Mexican trademark law.Luna participated as an expert on the interpretation of the Mexican patent law and patent utility requirements in a NAFTA arbitration examining the Canadian utility standard and doctrine of sound prediction. There are few opportunities for IP attorneys to participate in a Free Trade Agreement arbitration.He has been considered the first patent linkage litigator in the countryLuna advocate to have a direct and independent civil venue to claim damages derived from the violation of patent and trademark rights.AwardsChambers Global – Mexico, Band 1Chambers Latin America – IP, Band 1Chambers Latin America – Life Sciences, Band 1IAM Patent 1000 – Litigation, GoldLatin Lawyer 250, Tier 1Legal 500, Tier 1MIP – IP StarWho’s Who Legal, Tier 1World’s Guide to the Leading Patent Law Practitioners, Tier 1WTR 1000 – Silver – Enforcement & LitigationEducationFranklin Pierce Law CenterLLM, Intellectual Property Law, 2002Universidad PanamericanaDiploma on Amparo Law, 2000Universidad LatinoamericanaJuris Doctor, 1996Universidad Nacional Autónma de MéxicoDoctorate in Law, 2020
Alejandro Luna joined OLIVARES in 1996 and being made partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices. He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.
Alejandro Luna has been alternately dubbed “an extraordinary litigator, active at every level,” “responsive and insightful,” and “a knowledgeable IP practitioner offering creative and cost-effective advice” by his peers, according to IAM Patent 1000, while World Trademark Review’s WTR 1000 called him “a reliable ally for any party in a dispute”.
Since joining OLIVARES in 1996 and becoming partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices.
He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.
As one of the few patent and regulatory litigation experts in the country, Mr. Luna has played a crucial role in updating Mexico’s intellectual property (IP) system. He participated in questioning the constitutionality of certain provisions of Mexico’s Industrial Property Law and the Health Law and its regulation. He sponsored an important proposal to modify the litigation and enforcement systems that made it easier to obtain monetary compensation for violations of IP rights.
Mr. Luna spearheaded a more than a ten-year litigation strategy that incorporated regulation changes and lobbying, resulting in an important precedent for the patent linkage regulation and life terms of pipeline pharmaceutical patents in Mexico.
As a result of his involvement, Mr. Luna was selected as the delegate to represent the Asociación Mexicana de Industrias de Investigación Farmacéutica, AC (AMIIF), the industry association for R&D pharmaceutical companies that do business in Mexico, in negotiations concerning the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) agreement, the free trade agreement between Mexico and the European Union, and the United States-Mexico-Canada Agreement (USMCA/ T-MEC), which replaced NAFTA.
Mr. Luna’s practice is not devoted exclusively to life sciences; he represents clients across a myriad of industries. He has successfully litigated pharmaceutical patents and pioneered administrative court actions to seek recognition of DPE rights (regulatory data protection submitted to the regulatory agency), which are not specifically recognized under Mexican law.
His commitment to just and fair law extends to his overall promise of client satisfaction; he acts on behalf of his clients as an attorney and a lobbyist, pushing for changes to the law as necessary to best serve his clients.
Mr. Luna is also the author of several articles on patents, litigation, and regulatory issues in the pharmaceutical industries. He is part time professor at the Universidad Nacional Autónoma de México (UNAM), in the IP Master of Law and the Health Law program and recently obtained a Doctorate in Law (summa cum laude) with his doctoral thesis, titled “The Impact of International Treaties in the Mexican Patent Law, Pharmaceutical Patents and the Corresponding Enforcement”.
